

**IN THE CLAIMS:**

1. (Currently Amended): A pharmaceutical composition comprising an NO-releasing amount of the R(+) enantiomer of amlodipine or a pharmaceutically acceptable salt thereof, an anti-hypertensive amount of the S(-) enantiomer of amlodipine or a pharmaceutically acceptable salt thereof and a suitable excipient, diluent, or carrier, wherein the enantiomers are present in a ratio by weight (based on free base) of R(+) enantiomer: S(-) enantiomer of greater than 1:1 but less than 10:1.

2. (Cancelled).

3. (Original) A pharmaceutical composition according to Claim 1 wherein said ratio is in the range 2:1 to 8:1.

4. (Original) A pharmaceutical composition according to Claim 1 wherein said ratio is approximately 5:1.

5. (Original) A pharmaceutical composition according to Claim 1 which comprises a mixture of single crystals of the R(+) enantiomer or pharmaceutically acceptable salt thereof and single crystals of the S(-) enantiomer or pharmaceutically acceptable salt thereof.

6. (Original) A pharmaceutical composition according to Claim 5 wherein both enantiomers are in the form of pharmaceutically acceptable salts.

7. (Original) A pharmaceutical composition according to Claim 6 wherein the salts of both enantiomers have the same counter ion.
8. (Original) A pharmaceutical composition according to Claim 1 which comprises single crystals of the R(+) enantiomer or pharmaceutically acceptable salt thereof and mixed crystals containing both the R(+) enantiomer and the S(-) enantiomer or pharmaceutically acceptable salts of one or both thereof.
9. (Original) A pharmaceutical composition according to Claims 8 wherein the mixed crystals are racemic.
10. (Original) A pharmaceutical composition according to Claims 8 or 9 wherein the R(+) enantiomer is in the form of a pharmaceutically acceptable salt and the enantiomers in the mixed crystals are also in the form of pharmaceutically acceptable salts.
11. (Original) A pharmaceutical composition according to Claims 8 or 9 wherein the salt of the R(+) enantiomer and the salts of the enantiomers in the mixed crystals have the same counter ion.
12. (Original) A pharmaceutical composition according to Claim 1 which comprises mixed crystals containing both the R(+) enantiomer or pharmaceutically acceptable salt thereof and the S(-) enantiomer or pharmaceutically acceptable salt thereof.

13. (Original) A pharmaceutical composition according to Claim 12 wherein both enantiomers are in the form of pharmaceutically acceptable salts.
14. (Original) A pharmaceutical composition according to Claim 13 wherein the salts of both enantiomers have the same counter ion.
15. (Original) A pharmaceutical composition according to Claim 7 wherein said counter ion is mesylate or succinate.
16. (Original) A pharmaceutical composition according to Claim 11 wherein said counter ion is mesylate or succinate.
17. (Original) A pharmaceutical composition according to Claim 14 wherein said counter ion is mesylate or succinate.
18. (Original) A pharmaceutical composition according Claim 1 which is in the form of a tablet or capsule suitable for oral administration.
19. (Original) A pharmaceutical composition according Claim 1 which is in liquid dosage form.
20. (Original) A pharmaceutical composition according to Claim 1 which is in the form of a solution suitable for intravenous (iv) administration.

21. – 28. (Cancelled).

29. (Original): A pharmaceutical composition according to Claim 1 for use in the treatment of a condition for which a vascular NO-releasing agent is indicated.

30 – 32. (Cancelled).

33. (Original): A pharmaceutical composition according to Claim 1 suitable for use in a treatment of a condition for which both an anti-hypertensive and a vascular NO-releasing agent are indicated.

34. – 38. (Cancelled).